Priority Date: 20.03.12 (US 201261613046P)

COMBINATION THERAPY OF A MEK INHIBITOR AND IGF1R INHIBITOR

  • Application ID: EP13715486
  • Status: EXAMINATION IN PROGRESS

Applicants

Technology company logo small
Technology Company
Technology company logo small
Technology Company

Attorney

Employment test 51 - 200 employees
Company dna boult wade tennant ltd
no operation time available
Headquarter in London and 4 offices
active in Legal Services, IP Consulting, and IP Portfolio Processing

Specialization

This patent has the IPC combination A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) and C07 (ORGANIC CHEMISTRY) is specialized in the combination A61 and C07. We found, that TransMIT GmbH, Kailuweit & Uhlemann, Lederer Keller Patentanwälte Partnerschaft mbB, Vossius & Partner Patentanwälte Rechtsanwälte mbB, df-mp Dörries Frank-Molnia & Pohlman, Patentanwälte Rechtsanwälte PartG mbB and 190 others are specialized in all of these IPC classes. For a similar patent, they might be a good choice.

Timeline

  • 20.03.2012 - Priority Date (US 201261613046P)
  • 26.09.2013 - Publication A2 (WO2013142182)
  • 28.01.2015 - Publication A2 (EP2827901)

IPC Classification